Skip to main content
SpringerLink
Log in

Aldosterone and glomerular podocyte injury

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Aldosterone is traditionally viewed as a hormone regulating electrolyte and blood pressure homeostasis by acting on the distal nephron. Accumulating evidence suggests that aldosterone also plays pathogenetic roles in cardiovascular and renal injury. For example, aldosterone is a potent inducer of proteinuria. We demonstrated that podocyte injury underlies the pathogenesis of proteinuria in aldosterone-infused rats on a high salt diet. Mineralocorticoid receptor was detected in the podocytes in vivo and in vitro, and aldosterone caused induction of its effector kinase Sgk1, activation of NADPH oxidase and generation of reactive oxygen species. Selective aldosterone blocker eplerenone, as well as antioxidant tempol, ameliorated aldosterone-induced podocyte injury and proteinuria. Aldosterone was also involved in the podocyte damage and proteinuria of metabolic syndrome model SHR/NDmcr-cp. Adipocyte-derived aldosterone releasing factors were suggested to contribute to the aldosterone excess of this model. Furthermore, high salt diet markedly worsened the renal injury of SHR/NDmcr-cp. Although salt lowered serum aldosterone levels, it caused MR activation in the kidney. Accordingly, eplerenone dramatically improved the salt-evoked nephropathy. Taken together, aldosterone blockers can be an excellent therapeutic strategy for the treatment of podocyte injury, proteinuria, and cardiovascular and renal complications, not only in high aldosterone states but also in patients with activated MR signaling in the target tissue, whose circulating aldosterone level is not necessarily high. Addition of aldosterone blockers in patients treated with ACEIs or ARBs are also promising, because of “aldosterone breakthrough” phenomenon. Careful monitoring of hyperkalemia is necessary, especially in patients with impaired renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Simpson SA, Tait JF, Wettstein A, Neher R, von Euw J, Reichstein T. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia. 1953;9:333–5.

    Article  CAS  PubMed  Google Scholar 

  2. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364–72.

    Article  CAS  PubMed  Google Scholar 

  3. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–56.

    Article  CAS  PubMed  Google Scholar 

  4. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293:1107–12.

    Article  CAS  PubMed  Google Scholar 

  5. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395–401.

    Article  PubMed  Google Scholar 

  6. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002;970:89–100.

    Article  CAS  PubMed  Google Scholar 

  7. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227–35.

    Article  CAS  PubMed  Google Scholar 

  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    Article  CAS  PubMed  Google Scholar 

  10. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912–9.

    Article  CAS  PubMed  Google Scholar 

  11. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355–64.

    Article  CAS  PubMed  Google Scholar 

  12. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084–93.

    Article  CAS  PubMed  Google Scholar 

  13. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438–46.

    Article  CAS  PubMed  Google Scholar 

  14. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007;50:877–83.

    Article  CAS  PubMed  Google Scholar 

  15. Rozansky DJ. The role of aldosterone in renal sodium transport. Semin Nephrol. 2006;26:173–81.

    Article  CAS  PubMed  Google Scholar 

  16. Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2004;287:F593–601.

    Article  CAS  PubMed  Google Scholar 

  17. Knepper MA, Kim GH, Masilamani S. Renal tubule sodium transporter abundance profiling in rat kidney: response to aldosterone and variations in NaCl intake. Ann NY Acad Sci. 2003;986:562–9.

    Article  CAS  PubMed  Google Scholar 

  18. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86:1151–78.

    Article  CAS  PubMed  Google Scholar 

  19. Hou J, Speirs HJ, Seckl JR, Brown RW. Sgk1 gene expression in kidney and its regulation by aldosterone: spatio-temporal heterogeneity and quantitative analysis. J Am Soc Nephrol. 2002;13:1190–8.

    Article  CAS  PubMed  Google Scholar 

  20. Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, et al. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. Proc Natl Acad Sci USA. 2007;104:4025–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci USA. 1998;95:9424–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ronzaud C, Loffing J, Bleich M, Gretz N, Grone HJ, Schutz G, et al. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007;18:1679–87.

    Article  CAS  PubMed  Google Scholar 

  23. Hummler E, Barker P, Talbot C, Wang Q, Verdumo C, Grubb B, et al. A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism. Proc Natl Acad Sci USA. 1997;94:11710–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Pradervand S, Barker PM, Wang Q, Ernst SA, Beermann F, Grubb BR, et al. Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta-subunit of the amiloride-sensitive epithelial sodium channel. Proc Natl Acad Sci USA. 1999;96:1732–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wulff P, Vallon V, Huang DY, Volkl H, Yu F, Richter K, et al. Impaired renal Na(+) retention in the sgk1-knockout mouse. J Clin Invest. 2002;110:1263–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens. 2001;19:829–42.

    Article  CAS  PubMed  Google Scholar 

  27. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802–10.

    Article  CAS  PubMed  Google Scholar 

  28. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997;59:365–93.

    Article  CAS  PubMed  Google Scholar 

  29. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–800.

    Article  CAS  PubMed  Google Scholar 

  30. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43:841–8.

    Article  CAS  PubMed  Google Scholar 

  31. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906–12.

    Article  CAS  PubMed  Google Scholar 

  32. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005;16:2296–305.

    Article  CAS  PubMed  Google Scholar 

  33. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005;46:1039–45.

    Article  CAS  PubMed  Google Scholar 

  34. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension. 2005;46:1046–52.

    Article  CAS  PubMed  Google Scholar 

  35. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 2002;161:1773–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213–20.

    Article  CAS  PubMed  Google Scholar 

  37. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45:710–6.

    Article  CAS  PubMed  Google Scholar 

  39. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol. 2006;17:2193–201.

    Article  CAS  PubMed  Google Scholar 

  40. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266.

    Google Scholar 

  41. Ibrahim HN, Hostetter TH. Aldosterone in renal disease. Curr Opin Nephrol Hypertens. 2003;12:159–64.

    Article  CAS  PubMed  Google Scholar 

  42. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005;14:235–41.

    Article  CAS  PubMed  Google Scholar 

  43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329:1456–62.

    Article  CAS  PubMed  Google Scholar 

  44. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232–7.

    Article  CAS  PubMed  Google Scholar 

  46. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320–5.

    Article  PubMed  Google Scholar 

  47. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232–8.

    Article  CAS  PubMed  Google Scholar 

  48. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41:1021–6.

    Article  CAS  PubMed  Google Scholar 

  49. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990–6.

    Article  CAS  PubMed  Google Scholar 

  50. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.

    Article  CAS  PubMed  Google Scholar 

  51. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17:1362–72.

    Article  CAS  PubMed  Google Scholar 

  52. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–42.

    Article  CAS  PubMed  Google Scholar 

  53. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925–6.

    Article  CAS  PubMed  Google Scholar 

  54. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112:1435–43.

    Article  CAS  PubMed  Google Scholar 

  55. Artunc F, Amann K, Nasir O, Friedrich B, Sandulache D, Jahovic N, et al. Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1. J Mol Med. 2006;84:737–46.

    Article  CAS  PubMed  Google Scholar 

  56. Vallon V, Huang DY, Grahammer F, Wyatt AW, Osswald H, Wulff P, et al. SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess. Am J Physiol Regul Integr Comp Physiol. 2005;289:R395-401.

    Article  CAS  PubMed  Google Scholar 

  57. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354:1387–401.

    Article  CAS  PubMed  Google Scholar 

  58. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253–307.

    Article  CAS  PubMed  Google Scholar 

  59. Reiser J, Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7–1 in the pathogenesis of nephrotic syndrome. J Am Soc Nephrol. 2004;15:2246–8.

    Article  PubMed  Google Scholar 

  60. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1:575–82.

    Article  CAS  PubMed  Google Scholar 

  61. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286:312–5.

    Article  CAS  PubMed  Google Scholar 

  62. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24:349–54.

    Article  CAS  PubMed  Google Scholar 

  63. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24:251–6.

    Article  CAS  PubMed  Google Scholar 

  64. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54:1626–34.

    Article  CAS  PubMed  Google Scholar 

  66. Kretzler M, Koeppen-Hagemann I, Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch. 1994;425:181–93.

    Article  CAS  PubMed  Google Scholar 

  67. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772–9.

    Article  PubMed  Google Scholar 

  68. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ. Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol. 1998;274:F623–7.

    Article  CAS  PubMed  Google Scholar 

  69. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, et al. Catecholamines modulate podocyte function. J Am Soc Nephrol. 1998;9:335–45.

    CAS  PubMed  Google Scholar 

  70. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension. 2004;44:974–81.

    Article  CAS  PubMed  Google Scholar 

  71. Lewko B, Endlich N, Kriz W, Stepinski J, Endlich K. C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int. 2004;66:1001–8.

    Article  CAS  PubMed  Google Scholar 

  72. Nagase M, Ando K, Katafuchi T, Kato A, Hirose S, Fujita T. Role of natriuretic peptide receptor type C in Dahl salt-sensitive hypertensive rats. Hypertension. 1997;30:177–83.

    Article  CAS  PubMed  Google Scholar 

  73. Hino M, Nagase M, Kaname S, Shibata S, Nagase T, Oba S, et al. Expression and regulation of adrenomedullin in renal glomerular podocytes. Biochem Biophys Res Commun. 2005;330:178–85.

    Article  CAS  PubMed  Google Scholar 

  74. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65:30–9.

    Article  CAS  PubMed  Google Scholar 

  75. Yaoita E, Kawasaki K, Yamamoto T, Kihara I. Variable expression of desmin in rat glomerular epithelial cells. Am J Pathol. 1990;136:899–908.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res. 1997;236:248–58.

    Article  CAS  PubMed  Google Scholar 

  77. Mann CC. Public health. Provocative study says obesity may reduce U S life expectancy. Science. 2005;307:1716–7.

    Article  CAS  PubMed  Google Scholar 

  78. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337–50.

    Article  CAS  PubMed  Google Scholar 

  79. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. Jama. 2004;291:844–50.

    Article  CAS  PubMed  Google Scholar 

  80. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.

    Article  PubMed  Google Scholar 

  81. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.

    Article  PubMed  Google Scholar 

  82. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–80.

    Article  PubMed  Google Scholar 

  83. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440–7.

    Article  CAS  PubMed  Google Scholar 

  84. Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hypertens. 2002;11:331–5.

    Article  PubMed  Google Scholar 

  85. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.

    CAS  PubMed  Google Scholar 

  86. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481–6.

    Article  PubMed  Google Scholar 

  87. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.

    Article  PubMed  Google Scholar 

  88. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366:1059–62.

    Article  PubMed  Google Scholar 

  89. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.

    Article  PubMed  Google Scholar 

  90. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.

    Article  PubMed  Google Scholar 

  91. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–74.

    Article  CAS  PubMed  Google Scholar 

  92. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48:383–91.

    Article  PubMed  Google Scholar 

  93. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304:930–3.

    Article  CAS  PubMed  Google Scholar 

  94. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–62.

    Article  CAS  PubMed  Google Scholar 

  95. Ruano M, Silvestre V, Castro R, Garcia-Lescun MC, Rodriguez A, Marco A, et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg. 2005;15:670–6.

    Article  CAS  PubMed  Google Scholar 

  96. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43:41–7.

    Article  PubMed  CAS  Google Scholar 

  97. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239–45.

    Article  CAS  PubMed  Google Scholar 

  98. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K, et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet. 1996;14:130–1.

    Article  CAS  PubMed  Google Scholar 

  99. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10:7–13.

    Article  CAS  PubMed  Google Scholar 

  100. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518–24.

    Article  CAS  PubMed  Google Scholar 

  101. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.

    Article  CAS  PubMed  Google Scholar 

  102. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800–3.

    Article  CAS  PubMed  Google Scholar 

  103. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100:14211–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Stocco DM, Wang X, Jo Y, Manna PR. Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol Endocrinol. 2005;19:2647–59.

    Article  CAS  PubMed  Google Scholar 

  105. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358–63.

    Article  CAS  PubMed  Google Scholar 

  106. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98–101.

    Article  CAS  PubMed  Google Scholar 

  107. Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004;256:324–30.

    Article  CAS  PubMed  Google Scholar 

  108. Ritz E, Dikow R, Morath C, Schwenger V. Salt—a potential “uremic toxin?” Blood Purif. 2006;24:63–6.

    Article  CAS  PubMed  Google Scholar 

  109. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003;14:2775–82.

    Article  CAS  PubMed  Google Scholar 

  110. Farjah M, Roxas BP, Geenen DL, Danziger RS. Dietary salt regulates renal SGK1 abundance: relevance to salt sensitivity in the Dahl rat. Hypertension. 2003;41:874–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Miki Nagase & Toshiro Fujita

Authors
  1. Miki Nagase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiro Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miki Nagase.

Additional information

Presented at the 50th annual meeting of the Japanese Society of Nephrology.

About this article

Cite this article

Nagase, M., Fujita, T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 12, 233–242 (2008). https://doi.org/10.1007/s10157-008-0034-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-008-0034-9

Keywords

Search

Navigation